Article Information
History
- October 15, 2021.
Article Versions
- Version 1 (September 29, 2021 - 15:25).
- You are currently viewing Version 2 of this article (October 15, 2021 - 20:19).
- View Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Tsun-Yung Kuo1,2,
- Chia-En Lien1,3,
- Yi-Jiun Lin1,
- Meei-Yun Lin1,
- Chung-Chin Wu1,
- Wei-Hsuan Tang1,
- John D. Campbell4,
- Paula Traquina4,
- Ya-Shan Chuang1,
- Luke Tzu-Chi Liu1 and
- Charles Chen1,5,*
- 1Medigen Vaccine Biologics Corporation, Taipei City, Taiwan
- 2Department of Biotechnology and Animal Science, National Ilan University, Yilan County, Taiwan
- 3Institute of Public Health, National Yang-Ming Chiao Tung University, Taipei City, Taiwan
- 4Dynavax Technologies, Emeryville, CA 94608, USA
- 5Temple University, Philadelphia, PA 19122, USA
- ↵*Corresponding author: charles{at}medigenvac.com
Posted October 15, 2021.
Protection of Hamsters Challenged with SARS-CoV-2 Variants of Concern by Two Doses of MVC-COV1901 Vaccine Followed by a Single Dose of Beta Variant Version of MVC-COV1901
